<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methylnaltrexone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06800</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Methylnaltrexone is a pheriphally-acting &#956;-opioid antagonists that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. <span class="caps">FDA</span> approved in 2008.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06800/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06800/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06800.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06800.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06800.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06800.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06800.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06800">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>MNTX</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methylnaltrexone Bromide </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000116/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000116/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IFGIYSGOEZJNBE-KNLJMPJLSA-N</li>
              <li>Monoisotopic Mass: 435.104520972</li>
              <li>Average Mass: 436.339</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000116">DBSALT000116</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Relistor </td><td>Salix Pharmaceuticals Inc </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/narcotic-antagonists">Narcotic Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>73232-52-7</td></tr><tr><th>Weight</th><td>Average: 356.4354<br>Monoisotopic: 356.186183325</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>26</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>JVLBPIPGETUEET-GAAHOAFPSA-O</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22?/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-4-methyl-14-oxo-12-oxa-4-azapentacyclo[9.6.1.0&#185;,&#185;&#179;.0&#8309;,&#185;&#8311;.0&#8311;,&#185;&#8312;]octadeca-7,9,11(18)-trien-4-ium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CC[N+](C)(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Morphinans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Morphinans</td></tr><tr><th>Alternative parents</th><td>Benzylisoquinolines; Phenanthrenes and Derivatives; Isoquinolones and Derivatives; Tetralins; Benzofurans; Cyclohexanones; Alkyl Aryl Ethers; Phenols and Derivatives; Cyclohexanols; Piperidines; Tertiary Alcohols; Cyclic Alcohols and Derivatives; Enols; Polyamines</td></tr><tr><th>Substituents</th><td>phenanthrene; isoquinolone; tetralin; benzofuran; cyclohexanone; phenol derivative; cyclohexanol; alkyl aryl ether; piperidine; benzene; tertiary alcohol; cyclic alcohol; ketone; polyamine; ether; enol; amine; carbonyl group; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy. </td></tr><tr><th>Pharmacodynamics</th><td>Use of opioids induces slowing of gastrointestinal motility and transit. Following remifentanil administration, the methylnaltrexone and placebo groups showed no change in pupiliary constriction while the naloxone group showed a marked change over the time interval tested. </td></tr><tr><th>Mechanism of action</th><td>Methylnaltrexone is a pheriphally-acting &#956;-opioid antagonists that acts on the gastrointestinal tract inhibit opioid-induced decrease in gastric motility and transit time. Because methylnaltrexone is a quaternary derivative of naltrexone, it produces its gastrointestinal effects without producing analgesic effects or withdrawal symptoms as it does not cross the blood-brain-barrier. </td></tr><tr><th>Absorption</th><td>Methylnaltrexone is rapidly absorbed. 
Tmax (SubQ): 30 minutes (regardless of dose);
Cmax, 0.15 mg/kg SubQ dose = 117 ng/mL; 
AUC24, 0.15 mg/kg SubQ dose = 175 ng&#183;hr/mL; </td></tr><tr><th>Volume of distribution</th><td><p>Volume of distribution, steady state = 1.1 L/kg</p></td></tr><tr><th>Protein binding</th><td>11% to 15% bound to human plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>60% of the dose is metabolized. Conversion to methyl-6-naltrexol isomers (5% of total dose) and methylnaltrexone sulfate (1.3% of total dose) appear to be the primary pathways of metabolism. N&#8209;demethylation of methylnaltrexone to produce naltrexone is not significant. </p></td></tr><tr><th>Route of elimination</th><td>Most of the drug is eliminated as unchanged drug (85% of administered radioactivity). Approximately half of the dose is excreted in the urine and somewhat less in feces.</td></tr><tr><th>Half life</th><td>terminal: 8.89 &#177; 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous) </td></tr><tr><th>Clearance</th><td><p>10.5 &#177; 1.5 ml/min/kg (IV)</p></td></tr><tr><th>Toxicity</th><td>LD50: 50 mg/kg (primates); 
Orthostatic hypotension at plasma levels in excess of 1.400 ng/mL. The most common (&gt;5%) adverse reactions reported with methylnaltrexone bromide are abdominal pain, flatulence, nausea, dizziness, diarrhea and hyperhidrosis.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8138</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9268</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6681</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.9279</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9775</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.943</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5377</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7889</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.6417</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6999</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8884</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9271</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6213</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8552</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9521</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9803</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6301
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9561
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9528
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9409 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8578
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9042
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Subcutaneous</td><td>12 mg/0.6 mL </td></tr><tr><td>Injection, solution</td><td>Subcutaneous</td><td>8 mg/0.4 mL </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>